Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Polman

Showing results (281-290 of 290) with videos related to

Pageof 29
Sort By:
You have reached the last page of results.This site can display upto 290 results.
Neurology|August 24, 2005
Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI dataJ Sastre-Garriga, G T Ingle, M Rovaris, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Differential diagnosis of suspected multiple sclerosis: a consensus approachD H Miller, B G Weinshenker, M Filippi, et al.
Neurology|April 25, 2007
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSD H Miller, D Soon, K T Fernando, et al.
Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 2, 2013
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease durationH Kearney, M A Rocca, P Valsasina, et al.
Neurology|April 18, 2007
Natalizumab reduces visual loss in patients with relapsing multiple sclerosisL J Balcer, S L Galetta, P A Calabresi, et al.
Genes and Immunity|April 8, 2011
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosisS Vosslamber, L F van der Voort, I J van den Elskamp, et al.
Neurology|March 26, 2008
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessmentC H Polman, S C Reingold, F Barkhof, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2009
Proof of concept studies for tissue-protective agents in multiple sclerosisL R Mehta, S R Schwid, D L Arnold, et al.
Neurology|May 10, 2006
APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answersR M Burwick, P P Ramsay, J L Haines, et al.
Pageof 29

Showing results (281-290 of 290) with videos related to

Sort By:
Pageof 29
You have reached the last page of results.This site can display upto 290 results.
Neurology|August 24, 2005
Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI dataJ Sastre-Garriga, G T Ingle, M Rovaris, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Differential diagnosis of suspected multiple sclerosis: a consensus approachD H Miller, B G Weinshenker, M Filippi, et al.
Neurology|April 25, 2007
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSD H Miller, D Soon, K T Fernando, et al.
Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 2, 2013
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease durationH Kearney, M A Rocca, P Valsasina, et al.
Neurology|April 18, 2007
Natalizumab reduces visual loss in patients with relapsing multiple sclerosisL J Balcer, S L Galetta, P A Calabresi, et al.
Genes and Immunity|April 8, 2011
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosisS Vosslamber, L F van der Voort, I J van den Elskamp, et al.
Neurology|March 26, 2008
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessmentC H Polman, S C Reingold, F Barkhof, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2009
Proof of concept studies for tissue-protective agents in multiple sclerosisL R Mehta, S R Schwid, D L Arnold, et al.
Neurology|May 10, 2006
APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answersR M Burwick, P P Ramsay, J L Haines, et al.
Pageof 29